Member

This type of partnership for the prevention of illness is critical to achieving the Government’s ambition of reducing the burden on the NHS. AstraZeneca’s decision not to invest in Speke, Liverpool is therefore deeply disappointing and follows intensive work and collaboration between the Government and the company. This collaboration on Speke dates back to 2020 and led to an announcement at the Spring Budget 2024 when AstraZeneca set out its intention to invest £450 million into its flu vaccine manufacturing facility. To secure that investment, the previous Chancellor provided assurance of His Majesty’s Government support, valued at around £90 million, subject to successful completion of due diligence. That support was based on His Majesty’s Government’s initial assessment of figures provided by the company.